Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark's Lead Compound For COPD Fails; Forest To Wait For 2010 Studies In Asthma Patients

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Hopes of a novel drug to treat smoking-induced lung disease were dashed after India's Glenmark Pharma and its U.S.-based research partner Forest Labs announced that the compound under development in Phase IIb human trials failed to meet efficacy endpoints

You may also be interested in...



India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards

Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.

India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards

Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.

India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards

MUMBAI - After a prolonged decision-making process, India's Glenmark Pharmaceuticals is likely to halt development of potential compounds melogliptin (GRC 8200) and pain management drug GRC 6211

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel